RemeGen Co. Ltd. Class A RemeGen Co. Ltd. Class A

RemeGen Co. Ltd. Class A

688331

Rank in Stocks #2414
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Share Price
$14.49
Market Cap
$8.11B
Change (1 day)
2.99%
Change (1 year)
9.18%
Country
CN
Trade RemeGen Co. Ltd. Class A (688331)

Category

Healthcare
Stock split history for RemeGen Co. Ltd. Class A (688331)
RemeGen Co. Ltd. Class A stock (symbol: 688331) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One 688331 share bought prior to Oct 20, 2026 would equal to 0 688331 shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL